Physician profile
Patrick A Begley
NPI 1265880033
$1,640.62
in general payments reported to CMS, 2019-2025
17 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.43 · 2022: $152 · 2023: $482 · 2024: $531 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.22 | 2022-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $258.68 | 2022-2025 | |
| Exact Sciences Corporation | $243.01 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $137.29 | 2023-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $79.95 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Sanofi-Aventis U.S. LLC | $73.91 | 2025 | |
| Glaxosmithkline, LLC. | $73.56 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $68.03 | 2024 | Mounjaro, Zepbound |
| Abbvie INC. | $61.80 | 2021-2024 | Vraylar |
| Amgen INC. | $57.76 | 2024-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $56.81 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $45.74 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $45.62 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.77 | 2024 | Glassia |
| Itamar Medical INC | $37.37 | 2025 | Watchpatone |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.35 | 2023 | Quviviq |
| Corium, LLC | $15.75 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Begley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.